[177Lu]Lu-PSMA-597
/ Telix
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 20, 2026
Dose optimisation and PSMA receptor intensification with 177Lu-PSMA-597 in metastatic castration-resistant prostate cancer (mCRPC): The randomised phase II OPTIMAL-PSMA trial.
(ASCO-GU 2026)
- P2 | "Clinical Trial Registry Number: ACTRN12625000971437.. The full, final text of this abstract will be available on Feb 23 at 05:00 PM EST."
Clinical • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1